2.0000 0.00 (0.00%)
After hours: 4:36PM EDT
|Bid||1.9700 x 40700|
|Ask||2.0100 x 41800|
|Day's Range||1.9600 - 2.0100|
|52 Week Range||1.7300 - 6.1600|
|Beta (3Y Monthly)||2.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.67|
OPKO Health (OPK) delivered earnings and revenue surprises of 9.09% and 1.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
MIAMI, Aug. 07, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended June 30, 2019. Business Highlights.
Opko Health (NYSE: OPK ) unveils its next round of earnings this Wednesday, August 7. Here is Benzinga's everything-that-matters guide for the earnings announcement. Earnings and Revenue Analysts are predicting ...
MIAMI, Aug. 01, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) plans to report its operating and financial results for the three months ended June 30, 2019, as well as provide.
BioReference Laboratories, Inc., one of the largest clinical laboratories in the United States, today announced it has been selected by The IPA Association of America (TIPAAA) as its preferred provider of laboratory services and to assist with data analytics for its members’ patients. The agreement is designed to enhance patient care and offer collaborative health management tools to TIPAAA members, which includes more than 667 medical organizations representing over 303,000 MDs in 39 states. TIPAAA provides services that assist in improving the overall operations of Independent Physician Associations (IPAs) nationwide. Members will now have convenient access to BioReference’s comprehensive laboratory testing menu, including thousands of frequently requested routine and specialty tests, as well as the 4Kscore®, a blood test for detecting aggressive prostate cancer.
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Details the CEO buys this past week for the following companies: G-III Apparel Group, W&T; Offshore, HealthEquity, DXC Technology and OPKO Health Continue reading...
The largest Insider Buys this week were for Thor Industries Inc. (THO), Sinclair Broadcast Group Inc. (SBGI), OPKO Health Inc. (OPK), and Perspecta Inc. (PRSP). Continue reading...
OPKO Health (OPK) announced that its subsidiary, BioReference Laboratories, one of the largest clinical laboratories in the United States, has been selected by SOMOS, a physician-led network of more than 2,500 health care providers serving over 700,000 Medicaid beneficiaries in New York City, as its preferred provider of diagnostic testing and to assist with data analytics for its patients. This new collaboration is designed to streamline patient care and offer communication efficiencies between BioReference and the SOMOS network. SOMOS is New York City’s largest multi-cultural physician-led network that serves predominately underserved patient populations.
BioReference Laboratories, Inc., an OPKO Health (OPK) company and one of the largest clinical laboratories in the United States, has been selected by SOMOS, a physician-led network of more than 2,500 health care providers serving over 700,000 Medicaid beneficiaries in New York City, as its preferred provider of diagnostic testing and to assist with data analytics for its patients. This new collaboration is designed to streamline patient care and offer communication efficiencies between BioReference and the SOMOS network.
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued a new proposed local coverage determination (LCD) for the 4Kscore® test, with defined coverage criteria. Under the LCD, Medicare will reimburse the test for patients who meet the defined criteria. The full text of the updated LCD can be found here.
OPKO Health, Inc. (OPK) announces that the Company has submitted a de novo request to the U.S. Food and Drug Administration (FDA) seeking regulatory clearance for the 4Kscore® test. The 4Kscore® test is a blood test used by health care professionals to assess a patient’s risk of having aggressive prostate cancer after an abnormal prostate specific antigen (PSA) test result, and before a decision is made to perform a biopsy. The de novo pathway for approval is available to medical devices of low-to-moderate risk that do not have an approved predicate device. Per FDA guidelines, the Company expects to receive a response to this request within approximately 180 days.
He was among a group of individuals and companies, including billionaire Phillip Frost, who allegedly participated in a penny stock "pump and dump" scheme.
OPKO Health Inc NASDAQ/NGS:OPKView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for OPK with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding OPK are favorable, with net inflows of $2.95 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.